Skip to main content
Premium Trial:

Request an Annual Quote

This Week in Genome Research: Jan 6, 2010

In the advance, online edition of Genome Research, a group of investigators from Japan, Australia, and the UK came up with methods to account for the cross-mapping of an RNA sequences to incorrect loci. By analyzing small RNA high-throughput sequencing libraries using this correction, the team found evidence that mature miRNA editing occurs only rarely in animals.

David MacAlpine and his Duke University team evaluated the genome-wide origin recognition complex or ORC distribution patterns in Drosophila. They found that the DNA replication initiation factor localizes to parts of the chromosome that correspond to open chromatin — and that this ORC binding may be needed for subsequent cohesin complex loading in fruit flies.

An American, Australian, and Canadian research team investigated the role that replication timing plays in mouse embryonic stem cell differentiation by coming up with genome-wide replication-timing profiles for nearly two dozen mouse cell lines at ten early development stages and assessing transcription at seven of these developmental stages. The researchers found cell-type specific replication profiles and came up with what they call a "comprehensive 'fate map' of replication-timing changes during early mouse development."

National Institutes of Health researchers Yabin Guo and Henry Levin used high-throughput pyrosequencing to sequence retrotransposon insertion sites in the fission yeast Schizosaccharomyces pombe. Their results suggest the long terminal repeat retrotransposon Tf1 targets RNA polymerase II transcribed gene promoters — especially promoters that respond to stress. "This targeting of stress response genes coupled with the ability of Tf1 to regulate the expression of adjacent genes suggests Tf1 may improve the survival of S. pombe when cells are exposed to environmental stress," the duo writes.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.